



FLORIDA SOCIETY OF CLINICAL ONCOLOGY FAX BLAST – May 15, 2008

MESSAGE FROM FLASCO PRESIDENT: Robert Cassell, MD

I want to extend a special thanks to the FLASCO members who have provided our FLASCO Office with a list of NPs and PAs and all of their contact information in your office. This is going to be a great help with our 2008 ASCO Grant project.

CLINICAL PRACTICE COMMITTEE: Thomas Gaddis, MD, Chairman

New AHFS Compendium Indication for Vidaza®

The American Society of Health-System Pharmacists (ASHP) announced that Azacitidine (Vidaza®) has been accepted within its drug compendium as treatment for elderly patients (> 60 years of age) with acute myelogenous leukemia (AML). ASHP publishes the *American Hospital Formulary Service Drug Information (AHFS-DI)* compendium. The Oncology determination table may be found at: <http://www.ashp.org/ahfs/off-label-uses/azacitidine.pdf>

FCSO Incident to Update:

Earlier this week you should have received a special fax blast containing all of the updated information from FCSO regarding incident to – in the event you did not receive this information, please contact the FLASCO Executive Director.

FCSO UPDATES: FCSO Part A & Part B

Clinical Laboratory Fee Schedule Fact Sheet now Available

The *Clinical Laboratory Fee Schedule Fact Sheet*, which provides general information about the clinical laboratory fee schedule, coverage of clinical laboratory services, and how payment rates are set, is now available in print format from the Centers for Medicare & Medicaid Services *Medicare Learning Network*.

To place your order, visit <http://www.cms.hhs.gov/mlngeninfo/>, scroll down to “Related Links Inside CMS” and select “MLN Product Ordering Page.”

Clarification for Identifying Secondary Providers and NPI Roundtable Information

In accordance with the NPI final rule, when an identifier is reported on a paper or electronically submitted claim for ordering/referring/attending/operating/supervising/purchased service/other/service facility provider (in the x12N 837 claims transactions) or for prescriber (in the NCPDP 5.1 retail drug claim transaction), that identifier must be an NPI. For Medicare purposes, this requirement is effective May 23, 2008. If the entity to be identified as the ordering/referring/attending/operating/supervising/purchased service/other/service facility provider or prescriber does not furnish an NPI at the time of the order/referral/purchase or time of service, the billing provider must attempt to obtain that NPI in order to use it in the claim. The billing provider may use the NPI registry or may need to contact the ordering/referring/attending/operating/supervising/purchased service/other/service facility or prescriber in order to obtain the NPI. While the implementation guides for the X12N claims transactions permit the reporting of the social security number (SSN) for some secondary providers if there is no NPI, we do not believe the billing provider will be successful in the obtaining the SSN.

- If unable to obtain the NPI of the entity to be identified in the service facility location loop, no identifier should be reported in that loop.
- If unable to obtain the NPI of the ordering/referring/attending/operating/supervising/purchased service/other or prescriber, the billing provider (in the X12N 837 transactions) or the service provider (in the NCPDP 5.1 transaction) shall use its own NPI to identify those secondary providers. Medicare will not pay these claims if these secondary providers are not identified by NPIs.

CMS will Host NPI National Roundtable Q&A Session on May 19, 2008

CMS will host a national NPI roundtable Q&A session to address questions from the Medicare provider community prior to May 23, 2008. This roundtable will be on May 19, from 2-3:30 p.m. EDT. Questions will not be collected during the

registration process for this call. There will be no presentations during this call; we will open the lines to take questions following a brief introduction. For registration details, visit the CMS Web site at http://www.cms.hhs.gov/NationalProvIdentStand/Downloads/listserv_wording_5-19-08_call.pdf

FCSO PART A:

Duplicate Denials of Recovery Audit Contractor Inpatient Claims

The Centers for Medicare & Medicaid Services (CMS) has implemented billing instructions for providers to resubmit as ancillary (type of bill 12x) and outpatient (type of bill 13x) claims when the inpatient services were denied by the recovery audit contractor (RAC). First Coast Service Options, Inc. (FCSO) has identified that outpatient claims (TOB 13x) are rejecting as a duplicate of the inpatient claim that was previously denied by the RAC as the services provided not supporting admission into an inpatient stay. FCSO is investigating the issue and is in the process of implementing a solution to effectively process these rejected outpatient claims. Until this process is implemented, and due to the high volume of claims affected, providers may want to consider holding the resubmission of the outpatient claims (TOB 13x) until FCSO provides a status of the solution by posting a future notification on this Web site.

CMS UPDATES:

New:

MM5288 – Incident to Policy Update

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5288.pdf>

MM5921 – Therapy Personnel Qualifications and Policies Effective January 1, 2008

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5921.pdf>

MM5950 – Medicare Shared Systems Modifications Necessary to Capture and Crossover Medicaid Drug Rebate Data Submitted on Form UB 04 Paper Claims and Direct Data Entry (DDE) Claims

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5950.pdf>

MM6009 – July Quarterly Update to 2008 Annual Update of HCPCS Codes Used for Skilled Nursing Facility (SNF) Consolidated Billing (CB) Enforcement

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6009.pdf>

MM5979 – Assignment of Providers to Medicare Administrative Contractors

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5979.pdf>

Revised:

MM6000 – Ambulance Fee Schedule - Conversion Factor File for CY 2009 Ambulance Inflation Factor

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6000.pdf>

FDA ALERTS:

The FDA is asking that health professionals and facilities please review and examine all drug/device storage areas, including emergency kits, dialysis units and automated drug storage cabinets to ensure that all of the recalled heparin products have been removed and are no longer available for patient use. In addition, FDA would like to inform health professionals about other types of medical devices that contain, or are coated with, heparin. To read this update, and to learn how to report these problems to FDA, please go to: <http://www.fda.gov/cdrh/safety/heparin-healthcare-update.html>.

Please report to FDA adverse reactions associated with these devices, as well as any reactions associated with heparin or heparin flush solutions. If you have questions or would like more information about this request, please contact the Division of Drug Information at 301-796-3400

EDUCATIONAL OPPORTUNITIES:

Webinar on "Comparative Effectiveness." - AstraZeneca invites you to participate in an informative As you may already be aware, congress's move toward creating a national center on comparative effectiveness raises a big question for industry: "How will the data generated by this research be used by insurance companies?". This Webinar is offered through the Xcenda division of AmeriSourceBergen Specialty Group free of charge on Tuesday, May 20, 2008 from 1:00 to 2:00pm Central Daylight Time. To register, please go to <http://abswebcasts.com>

ImClone Systems Incorporated

Web based reimbursement updates available.

1. "2008 Washington Update" authored by Dr. Joseph Bailes, M.D.
2. "2008 Reimbursement and Coding Changes" authored by Bobbi Buell

If you are interested in having an ImClone representative visit your office and present one or both of these programs, please contact Bob Bexley at Bob.Bexley@imclone.com or call 770-331-4453.

Webcasts “Case Discussions in metastatic Breast Cancer.” Lilly Oncology invites you to participate in this webcast.

Speaker: Denise Yardley, MD, Program Director, Breast Cancer Research, The Sarah Cannon Research Institute.

Webcasts are offered as follows: May 22, 1:15 PM, and May 29, 3:15 PM (all EST). To register:

<http://www.medconference.net/breast>

DISCLAIMER: FLASCO has not reviewed these programs and “any views presented are not the views of FLASCO”

CORPORATE MEMBERSHIP/SPONSORSHIP: (January 1 – December 31, 2008)

FLASCO Members extends a big thanks to all of our 2008 Corporate Members/Sponsors

PLATINUM

Astra Zeneca
Bayer/Onyx
Cephalon Oncology
Eli Lilly
Oncology Supply/ION
Sanofi-Aventis
OPR
Pharmion
AMGEN
Genentech
Abraxis Oncology.
Ortho Biotech

GOLD

Celgene
Genomic Health
Novartis
Pfizer
Roche
GlaxoSmithKline
Bristol Myers Squibb
Wyeth

SILVER

MGI Pharma
US Oncology
ImClone Systems
OSI Pharmaceuticals
Millennium Pharmaceuticals, Inc.

BRONZE

Boehringer Ingelheim
Pharmaceuticals, Inc.
Alexion

FLASCO EVENTS:

August 8-9, 2008 – FLASCO Executive Committee Retreat – Marriott World Center Hotel - Orlando

November 7-8, 2008 – FLASCO Fall Meeting – Tampa Airport Marriott Hotel

February 27 & 28, 2009 – FLASCO Spring Meeting – Marriott Sawgrass - Jacksonville

FLASCO Contact Information: Dorothy Green Phillips, Executive Director -3709W. Jetton Ave., Tampa, Florida 33629 - Tel: 800.444.1410, Ext. 4410 - Cell Phone: 813.294.2620 - Fax: 813.349-4410 or 813.349.4472
Email: Dorothy.Green@cancer.org

OTHER EVENTS:

May 30 – June 4, 2008 – ASCO Annual Meeting - Chicago

September 17-20, 2008 – ACCC 25th National Oncology Economic Conference – San Francisco, California

September 19-20, 2008 - Annual ASCO/ASH/SGO Meeting of the Hematology/Oncology CAC Network

September 25-28, 2008 - Oncology Congress - the Hilton San Francisco

December 6-9, 2008 – ASH Annual meeting – San Francisco

February 5-8, 2009 - Florida Joint Cancer Conference – Orlando

February 26-28, 2009 – ASCO - GU Symposium, Orlando World Center Marriott

March 22-24, 2009 - 2009 AOHA Assembly Conference – Los Angeles, California